Medicamen Biotech Ltd. (MEDICAM) Share Price Rises 8.2% Today
- August 4, 2026
- Posted by: Harsh Piplani
- Category: News
Medicamen Biotech Ltd. Share Price rises 8.2% to Rs 258, with a market cap of Rs 320.01 Cr. Explore today’s price action and sector analysis.
Medicamen Biotech Ltd. Share Price has experienced a significant rise today, closing at Rs 258, marking an 8.2% increase from the previous close of Rs 238.45. This price movement has brought the company’s market capitalisation to Rs 320.01 crore, placing it in the Micro Cap category.
Today’s price action positions Medicamen Biotech Ltd. among the top gainers in the market. The Pharmaceuticals & Drugs industry, part of the broader Healthcare sector, has seen varied performance, and this move by Medicamen Biotech Ltd. stands out. While the data confirms the price event, it does not establish a specific catalyst for today’s rise. Investors and analysts will be keen to explore the underlying factors contributing to this upward movement.
Medicamen Biotech Ltd. (MEDICAM) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 258 |
| Previous Close | Rs 238.45 |
| Today's Change | +Rs 19.55 (+8.2%) |
| Day Open | Rs 244.05 |
| Day High | Rs 258 |
| Day Low | Rs 240.75 |
| Current Volume (BSE) | 1,192 |
| BSE Traded Volume | 1,192 |
| NSE Traded Volume | 22,855 |
| Combined NSE + BSE Volume | 24,047 |
| Turnover | Rs 0.03 crore |
| Market Capitalisation | Rs 320.01 crore |
| Market Cap Category | Micro Cap |
Medicamen Biotech Ltd. (MEDICAM) traded at Rs 258. versus the previous close of Rs 238.45, a rise of 8.2%. The stock opened at Rs 244.05, reached Rs 258, touched Rs 240.75. Reported volume was 1,192.
Medicamen Biotech Ltd. (MEDICAM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 320.01 crore |
| P/E Ratio | 33.54x |
| P/B Ratio | 1.2x |
| ROE | 9.89% |
| ROCE | 12.99% |
| EPS | Rs 7.11 |
| Dividend Yield | 0.42% |
Medicamen Biotech Ltd. was valued at a P/E ratio of 33.54x, a P/B ratio of 1.2x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 9.89% and ROCE of 12.99%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 7.11, dividend yield of 0.42%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Medicamen Biotech Ltd. has a market capitalisation of Rs 320.01 crore. The company’s price-to-earnings (P/E) ratio is 33.54, and its price-to-book (P/B) ratio is 1.2. These valuation metrics provide insight into how the market values the company relative to its earnings and book value.
The return on equity (ROE) is 9.89%, and the return on capital employed (ROCE) is 12.99%. These figures indicate the company’s efficiency in generating returns on shareholder equity and capital employed. The earnings per share (EPS) is Rs 7.11, reflecting the earnings attributable to each share. The dividend yield is 0.42%, indicating the historical payout relative to the current price.
In the context of the Healthcare sector, Medicamen Biotech Ltd.’s P/E ratio is above the industry median of 25.88 but below the average of 69.32. The company’s ROE is slightly below the industry median of 10.7 but above the average of 8.25. These comparisons provide a nuanced view of the company’s valuation and profitability within its sector.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 33.54x |
| Benchmark Median P/E | 25.88x |
| Benchmark Average P/E | 69.32x |
| Benchmark P/E Range | 3.41x to 3,364.06x |
| Company P/B Ratio | 1.2x |
| Benchmark Median P/B | 1.77x |
| Company ROE | 9.89% |
| Benchmark Median ROE | 10.7% |
| Company ROCE | 12.99% |
| Benchmark Median ROCE | 12.98% |
| Company Market Capitalisation | Rs 320.01 crore |
| Benchmark Median Market Cap | Rs 146.46 crore |
Medicamen Biotech Ltd. (MEDICAM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 33.54x, which is above the benchmark median of 25.88x, a difference of +29.6%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Medicamen Biotech Ltd. (MEDICAM) has a ROE of 9.89%, which is below the benchmark median of 10.7%, a difference of -7.57%. Medicamen Biotech Ltd. (MEDICAM) has a ROCE of 12.99%, which is above the benchmark median of 12.98%, a difference of +0.08%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
The Healthcare sector, specifically the Pharmaceuticals & Drugs industry, comprises 137 companies. Medicamen Biotech Ltd.’s P/E ratio of 33.54 is above the industry median of 25.88, suggesting a higher valuation relative to many peers. However, it remains below the industry average of 69.32, indicating a more moderate valuation compared to some outliers.
The company’s P/B ratio of 1.2 is below the industry median of 1.77 and the average of 2.48, suggesting a relatively lower valuation based on book value. The ROE of 9.89% is slightly below the industry median of 10.7% but above the average of 8.25%, indicating competitive profitability. The ROCE of 12.99% aligns closely with the industry median of 12.98% but is below the average of 15.71%.
Overall, Medicamen Biotech Ltd. is positioned within a diverse industry with varying valuations and profitability metrics. The company’s performance today highlights its potential within the sector, and investors may consider these factors when evaluating its prospects.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,931.84 | 0 | 0.76 | -2.89 | -0.26 |
| Hikal Ltd. | HIKAL | 2,731.11 | 0 | 2.37 | 15.22 | 16.15 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,683.28 | 39.39 | 7.98 | 28.21 | 26.35 |
| Panacea Biotec Ltd. | PANACEABIO | 2,580.49 | 0 | 9.08 | 0 | 5.36 |
| Beta Drugs Ltd. | BETA | 2,474.26 | 62.88 | 9.95 | 18.65 | 22.17 |
Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 33.54x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 9.89% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 12.99% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Medicamen Biotech Ltd. (MEDICAM) has a market capitalisation of Rs 320.01 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
When compared to its peers, Medicamen Biotech Ltd. exhibits a P/E ratio of 33.54, which is lower than Beta Drugs Ltd.’s 62.88 and Kwality Pharmaceuticals Ltd.’s 39.39 but higher than Hester Biosciences Ltd.’s 15.25. The company’s P/B ratio of 1.2 is lower than Kwality Pharmaceuticals Ltd.’s 7.98 and Beta Drugs Ltd.’s 9.95, indicating a more conservative valuation.
In terms of profitability, Medicamen Biotech Ltd.’s ROE of 9.89% is lower than Kwality Pharmaceuticals Ltd.’s 28.21% and Beta Drugs Ltd.’s 18.65%. The ROCE of 12.99% is also lower than Kwality Pharmaceuticals Ltd.’s 26.35% and Beta Drugs Ltd.’s 22.17%. These comparisons provide a perspective on the company’s relative strengths and weaknesses within the industry.
Why Investors Are Watching Medicamen Biotech Ltd.
Investors are closely monitoring Medicamen Biotech Ltd. due to its recent price rise and position within the Healthcare sector. The company’s technical indicators, such as the elevated RSI, suggest strong momentum, while its fundamental metrics provide insights into its valuation and profitability.
- Price Action: Significant 8.2% rise today.
- Technical Position: Elevated RSI indicates strong momentum.
- Fundamental Context: Competitive P/E and ROE within the sector.
- Sector Positioning: Positioned in a diverse industry with varying valuations.
Investors should continue to monitor Medicamen Biotech Ltd.’s performance, particularly its technical indicators and sector dynamics, to assess future opportunities and risks.
About Medicamen Biotech Ltd.
Medicamen Biotech Ltd. operates within the Pharmaceuticals & Drugs industry, a segment of the broader Healthcare sector. The company is involved in the development, manufacturing, and marketing of pharmaceutical products. Its product portfolio includes a range of formulations catering to various therapeutic areas.
With a focus on quality and innovation, Medicamen Biotech Ltd. aims to meet the healthcare needs of its customers. The company’s operations are supported by a robust manufacturing infrastructure and a commitment to research and development. As a player in the competitive Pharmaceuticals & Drugs industry, Medicamen Biotech Ltd. continues to explore opportunities for growth and expansion.
Track Medicamen Biotech Ltd. Share Price on Univest
Use Medicamen Biotech Ltd. (MEDICAM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors can track Medicamen Biotech Ltd. Share Price on Univest to access live updates on share price, technical indicators, fundamental ratios, and more. Univest provides comprehensive market insights, including shareholding patterns, 52-week levels, and sector performance, enabling investors to make informed decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Medicamen Biotech Ltd.?
Ans. The current share price of Medicamen Biotech Ltd. is Rs 258, reflecting an 8.2% increase from the previous close of Rs 238.45. The stock moved 8.2% during the session. The intraday range extended from Rs 240.75 to Rs 258.
Why did Medicamen Biotech Ltd. share price rise today?
Ans. The share price of Medicamen Biotech Ltd. rose by 8.2% today, but the data does not establish a specific catalyst for this price rise. The stock moved 8.2% during the session.
What is the market capitalisation of Medicamen Biotech Ltd.?
Ans. Medicamen Biotech Ltd. has a market capitalisation of Rs 320.01 crore, categorising it as a Micro Cap company. The company operates in the Healthcare sector. Its P/E ratio is 33.54x.
How does Medicamen Biotech Ltd.'s P/E ratio compare to the industry?
Ans. Medicamen Biotech Ltd.'s P/E ratio of 33.54 is above the industry median of 25.88 but below the average of 69.32. The company trades at a P/E ratio of 33.54x. Its P/B ratio is 1.2x.
How does Medicamen Biotech Ltd.'s ROE compare to its peers?
Ans. Medicamen Biotech Ltd.'s ROE of 9.89% is lower than some peers like Kwality Pharmaceuticals Ltd. with 28.21%. ROE stands at 9.89%. ROCE stands at 12.99%. The relevant peer median ROE is 10.7%.
What is the P/B ratio of Medicamen Biotech Ltd.?
Ans. Medicamen Biotech Ltd. has a P/B ratio of 1.2, which is below the industry median of 1.77. The company trades at a P/E ratio of 33.54x. Its P/B ratio is 1.2x.
How does Medicamen Biotech Ltd.'s ROCE compare to the industry?
Ans. Medicamen Biotech Ltd.'s ROCE of 12.99% aligns closely with the industry median of 12.98% but is below the average of 15.71%. ROE stands at 9.89%. ROCE stands at 12.99%. The relevant peer median ROE is 10.7%.
